Today's Rundown Featured Story | | | Thursday, March 5, 2020 Cellectis has revised its deal with Servier, granting its partner worldwide rights to all its CD19 CAR-T therapies in return for €25 million ($27.6 million) and the control of candidates against five additional targets. |
|
|---|
|
Top Stories Thursday, March 5, 2020 AMAG Pharmaceuticals is losing its CEO, likely having a drug pulled off the market by the FDA and has cut more than 100 staffers; as it turns more deeply to its pipeline, the person in charge of that is now leaving. Thursday, March 5, 2020 PsiOxus Therapeutics has hired Tom Lillie away from Merck to work as its chief medical officer. Lillie’s arrival coincides with the initiation of a phase 1 trial of PsiOxus’ quadrivalent viral gene therapy vector. Thursday, March 5, 2020 Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas. Thursday, March 5, 2020 Just a month after getting its BLA accepted by the FDA for its next-gen breast cancer hopeful, MacroGenics’ SVP of clinical development and CMO Jon Wigginton, M.D., is set to leave the company later this month. Wednesday, March 4, 2020 Scientists at City of Hope have designed a novel chimeric antigen receptor (CAR) based on chlorotoxin (CLTX), a toxin found in scorpion venom. The novel CAR-T cell therapy successfully killed glioblastoma tumors with minimal off-target events and will now be ushered into clinical testing. Wednesday, March 4, 2020 The FDA has exercised a rarely used authority to completely ban a product from the market: the use of electric shock devices for conditioning a person against self-harm or aggressive behaviors. Thursday, March 5, 2020 Moderna's vaccine is nearly set for testing as investigators recruit trial participants in the Seattle area. The biotech's CEO, Stephane Bancel, has pledged to be "thoughtful" about the price. Meanwhile, the U.S. House of Representatives passed a major spending bill that includes billions for R&D and $300 million to purchase potential vaccines and therapeutics for the public. Enrollment Showcase | | | Presented by: Global EMBA for Healthcare & the Life Sciences, University of Toronto Prepare to step up in your career, build the expertise you need to reshape your organization, and explore opportunities worldwide. |
|
|---|
|
Resources Sponsored by: Metabolon Metabolomics can help you streamline your drug development process by providing the framework to make a stronger, more confident, and more valuable case for a molecule in a shorter timeframe. Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Reprints Desk/Research Solutions 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Baxter When different drug products are produced in shared facilities, potential for cross-contamination needs to be addressed. Outsourcing to a CMO with experience in multiproduct facilities can be an option. Sponsored by: WCG Metrics Champion Consortium Ineffective measurement could mean wasting both time and money. This whitepaper showcases a custom-built Metric Maturity Model that helps illustrate and define the process for measuring the right things the right way. Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates by implementing the right methodology with a focus on behavior change. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 
